Feasibility and safety of orbital atherectomy for the treatment of in‐stent restenosis secondary to stent under‐expansion

Abstract

OA can be effectively performed as an adjunctive tool in the treatment of ISR with balloon undilatable SU. The use of OA for SU is not approved by the U.S. Food and Drug Administration and is "off label" and caution must be used to limit any device/stent interaction.